{
    "clinical_study": {
        "@rank": "132823", 
        "arm_group": [
            {
                "arm_group_label": "afatinib", 
                "arm_group_type": "Experimental", 
                "description": "oral intake, once daily"
            }, 
            {
                "arm_group_label": "methotrexate", 
                "arm_group_type": "Active Comparator", 
                "description": "intravenous bolus injection, once weekly"
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, open-label, phase III study will be performed in patients with recurrent\n      and/or metastatic head and neck cancer which has progressed after platinum-based therapy.\n      The objectives of this trial are to compare the efficacy and safety of afatinib versus\n      methotrexate."
        }, 
        "brief_title": "LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma, Squamous Cell", 
                "Neoplasms, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity,\n             oropharynx, hypopharynx or larynx, which has recurred/metastasised and is not\n             amenable for salvage surgery or radiotherapy.\n\n          2. Documented progressive disease based on investigator assessment according to RECIST,\n             following receipt of a cisplatin and/or carboplatin based regimen administered for\n             recurrent and/or metastatic disease independent of whether patient progressed during\n             or after platinum based therapy.\n\n          3. Measurable disease according to RECIST (version 1.1).\n\n          4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at Visit 2.\n\n          5. Male and female patients age is 18 years or older\n\n          6. Signed and dated written informed consent that is in compliance with ICH-GCP and\n             local law.\n\n        Exclusion criteria:\n\n          1. Progressive disease within three months after completion of curatively intended\n             treatment for locoregionally advanced or for metastatic head and neck squamous cell\n             cancer (HNSCC).\n\n          2. Primary tumour site nasopharynx (of any histology), sinuses, and/or salivary glands.\n\n          3. Any other than one previous platinum based systemic regimen given for recurrent\n             and/or metastatic disease. Re-challenge with the first line regimen after a temporary\n             break is considered a second line regimen only in case of progression within the\n             break.\n\n          4. Prior treatment with EGFR-targeted small molecules.\n\n          5. Treatment with any investigational drug or anti-cancer therapy less than four weeks\n             prior to randomization (except palliative radiotherapy to bones to alleviate pain).\n\n          6. Unresolved chronic toxicity, other than hearing loss, tinnitus or dry mouth, CTCAE\n             grade >2 from previous anti-cancer therapy or unresolved skin toxicities CTCAE grade\n             >1 and/or diarrhoea CTCAE grade >1 caused by prior treatment with EGFR targeted\n             antibodies.\n\n          7. Previous tumour bleeding CTCAE grade =3.\n\n          8. Requirement for treatment with any of the prohibited concomitant medications.\n\n          9. Major surgical or planned procedure less than four weeks prior to randomization\n             (isolated biopsies are not considered as major surgical procedures).\n\n         10. Any other malignancy unless free of disease for at least five years except for:\n\n               1. Other HNSCC of a location as described in inclusion criterion number 1\n\n               2. Appropriately treated superficial basal cell skin cancer\n\n               3. Surgically cured cervical cancer in situ\n\n               4. For Korea: endoscopically cured superficial esophageal and/or gastric cancer is\n                  allowed\n\n         11. Known lesion or signs of brain metastasis.\n\n         12. Known pre-existing interstitial lung disease (ILD).\n\n         13. Clinically relevant cardiovascular abnormalities, as judged by the investigator, such\n             as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA\n             classification =III, unstable angina, myocardial infarction within six months prior\n             to randomization, or poorly controlled arrhythmia.\n\n         14. Cardiac left ventricular dysfunction with resting ejection fraction <lower limit of\n             normal (LLN) of investigational site (if no LLN is defined at the site the lower\n             limit is 50%).\n\n         15. Significant or recent acute gastrointestinal disorders with diarrhoea as a major\n             symptom in the opinion of the investigator, e.g. Crohn's disease, malabsorption or\n             CTCAE grade >1 diarrhoea of any aetiology at randomization.\n\n         16. Known HIV, active hepatitis B, active hepatitis C, and/or other known severe\n             infections, including but not limited to tuberculosis, as judged by the investigator.\n\n         17. Other significant disease that in the investigator's opinion would exclude the\n             subject from the trial.\n\n         18. Screening laboratory values:\n\n               1. Absolute neutrophil count (ANC) <1.5x10^9/l\n\n               2. Platelet count <75x10^9/l\n\n               3. Total bilirubin >1.5 times the upper limit of normal (ULN)\n\n               4. Aspartate amino transferase (AST) or alanine amino transferase (ALT) >3 times\n                  the ULN (if related to liver metastases >5 times the ULN)\n\n               5. Calculated creatinine clearance <50 ml/min (as evidenced by using the\n                  Cockcroft-Gault formula).\n\n         19. Women of child-bearing potential and men who are able to father a child, unwilling to\n             be abstinent or to use adequate contraception during the trial and for at least six\n             months after end of treatment. Adequate methods of contraception and definition of\n             child-bearing potential.\n\n         20. Pregnancy or breast feeding.\n\n         21. Known or suspected hypersensitivity to any of the study medications or their\n             excipients.\n\n         22. Any past or present history of areca/betel-nut chewing or its derivatives for a\n             cumulative duration of more than 3 months\n\n         23. Patients unable to comply with the protocol, in the opinion of the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856478", 
            "org_study_id": "1200.161"
        }, 
        "intervention": [
            {
                "arm_group_label": "methotrexate", 
                "description": "intravenous bolus injection, once weekly", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "afatinib", 
                "description": "oral intake, once daily", 
                "intervention_name": "afatinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methotrexate"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86015 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86019 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bengbu", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86017 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86014 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86020 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86016 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haerbin", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86013 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86021 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86018 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86022 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "1200.161.86010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alexandria", 
                        "country": "Egypt"
                    }, 
                    "name": "1200.161.20003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cairo", 
                        "country": "Egypt"
                    }, 
                    "name": "1200.161.20001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dakahlia", 
                        "country": "Egypt"
                    }, 
                    "name": "1200.161.20002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hongkong", 
                        "country": "Hong Kong"
                    }, 
                    "name": "1200.161.85201 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shatin", 
                        "country": "Hong Kong"
                    }, 
                    "name": "1200.161.85202 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amravati", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurangabad", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91014 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangalore", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baroda", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bikaner", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91020 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cuttack", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91011 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Delhi", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyderabad", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91019 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolkata, West Bengal", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lucknow", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madurai, Tamil Nadu", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mumbai", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91015 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mysore", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91018 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagpur", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91017 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagpur", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nasik", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91016 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pune", 
                        "country": "India"
                    }, 
                    "name": "1200.161.91008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyang", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.161.82003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.161.82005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.161.82001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.161.82004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "1200.161.82002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cebu City", 
                        "country": "Philippines"
                    }, 
                    "name": "1200.161.63001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines"
                    }, 
                    "name": "1200.161.63002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Keelung City", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.161.88603 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.161.88602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "1200.161.88601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiang Mai", 
                        "country": "Thailand"
                    }, 
                    "name": "1200.161.66001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phitsanulok", 
                        "country": "Thailand"
                    }, 
                    "name": "1200.161.66003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Songkla", 
                        "country": "Thailand"
                    }, 
                    "name": "1200.161.66002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "China", 
                "Egypt", 
                "Hong Kong", 
                "India", 
                "Korea, Republic of", 
                "Philippines", 
                "Taiwan", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "Egypt: Ministry of Health and Population", 
                "Hong Kong: Department of Health", 
                "India: Drugs Controller General of India", 
                "Philippines: Department of Health", 
                "South Korea: Ministry of Food and Drug Safety (MFDS)", 
                "Taiwan : Food and Drug Administration", 
                "Thailand: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression free survival (PFS), defined as the time from the date of randomization to the date of progression evaluated according to RECIST 1.1 or to the date of death, whichever occurs first", 
            "safety_issue": "No", 
            "time_frame": "up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856478"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival (OS), defined as the time from the date of randomization to the date of death (regardless of the cause of death)", 
                "safety_issue": "No", 
                "time_frame": "up to 3 years"
            }, 
            {
                "measure": "Objective response defined as complete response (CR) or partial response (PR) determined by RECIST 1.1 according to the best response to study medication", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }, 
            {
                "measure": "Health related quality of life (HRQOL) will be assessed based on patient-reported questionaires", 
                "safety_issue": "No", 
                "time_frame": "up to 2 years"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}